Crit Care Med:外科重症监护患者铁调素和贫血!

2018-03-08 xing.T MedSci原创

由此可见,入住ICU时铁调素血清浓度明显增加,并在ICU停留期间(28天)显著降低。降低的铁调素浓度与增加的网织红细胞反应和通过减少IL-6和C反应蛋白浓度来体现减弱的炎症反应有关,但与贫血痊愈无关。

炎症性贫血在ICU患者中很常见,并且铁调素是铁代谢的关键调节因子。近日,危重病医学领域权威杂志Critical Care Medicine上发表了一篇研究文章,研究人员评估了外科ICU贫血患者铁调素、促红细胞生成素、铁和炎症标志物随时间的变化。

该研究是在美国大学医院外科重症监护病房进行的前瞻性单中心临床干预研究。参与者为一百例外科成年ICU患者。研究人员在受试者入住ICU和28天一系列时间点对血清铁调素、血液和红细胞生成的时间依赖性变化进行了研究,并评估了血液与铁参数和炎症反应之间的相关性。

平均血清铁调素水平在ICU入院时显著上升,并随着时间推移而下降(144-36ng/ml;P<0.0001)。尽管网织红细胞计数增加(1.3-2.9%),平均血清促红细胞生成素水平仍然很低(29-44mU/ml),并且血红蛋白没有显著改变。铁调素与红细胞输血、C反应蛋白、白介素-6、铁蛋白呈正相关,而与铁、总铁结合力、转铁蛋白和网织红细胞反应呈负相关。铁调素与血清中肿瘤坏死因子α浓度无关。回归分析表明铁蛋白、C反应蛋白和网织红细胞数可预测当天铁调素;铁调素和C-反应蛋白可预测当天的网织红细胞计数。

由此可见,入住ICU时铁调素血清浓度明显增加,并在ICU停留期间(28天)显著降低。降低的铁调素浓度与增加的网织红细胞反应和通过减少IL-6和C反应蛋白浓度来体现减弱的炎症反应有关,但与贫血痊愈无关。

原始出处:

Cherry-Bukowiec,et al. Hepcidin and Anemia in Surgical Critical Care: A Prospective Cohort Study.critical care medicine. https://journals.lww.com/ccmjournal/toc/publishahead

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2018149, encodeId=4e352018149f3, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Fri Sep 28 17:35:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360390, encodeId=e5221360390f8, content=<a href='/topic/show?id=fe70965643d' target=_blank style='color:#2F92EE;'>#铁调素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96564, encryptionId=fe70965643d, topicName=铁调素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551129, encodeId=fd171551129d7, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608618, encodeId=4f0d1608618a9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294671, encodeId=f5702946e11f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 10 05:33:05 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294373, encodeId=c8e72943e3d6, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Mar 09 06:00:25 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2018149, encodeId=4e352018149f3, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Fri Sep 28 17:35:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360390, encodeId=e5221360390f8, content=<a href='/topic/show?id=fe70965643d' target=_blank style='color:#2F92EE;'>#铁调素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96564, encryptionId=fe70965643d, topicName=铁调素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551129, encodeId=fd171551129d7, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608618, encodeId=4f0d1608618a9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294671, encodeId=f5702946e11f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 10 05:33:05 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294373, encodeId=c8e72943e3d6, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Mar 09 06:00:25 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2018149, encodeId=4e352018149f3, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Fri Sep 28 17:35:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360390, encodeId=e5221360390f8, content=<a href='/topic/show?id=fe70965643d' target=_blank style='color:#2F92EE;'>#铁调素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96564, encryptionId=fe70965643d, topicName=铁调素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551129, encodeId=fd171551129d7, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608618, encodeId=4f0d1608618a9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294671, encodeId=f5702946e11f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 10 05:33:05 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294373, encodeId=c8e72943e3d6, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Mar 09 06:00:25 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
    2018-03-10 bioon6
  4. [GetPortalCommentsPageByObjectIdResponse(id=2018149, encodeId=4e352018149f3, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Fri Sep 28 17:35:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360390, encodeId=e5221360390f8, content=<a href='/topic/show?id=fe70965643d' target=_blank style='color:#2F92EE;'>#铁调素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96564, encryptionId=fe70965643d, topicName=铁调素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551129, encodeId=fd171551129d7, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608618, encodeId=4f0d1608618a9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294671, encodeId=f5702946e11f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 10 05:33:05 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294373, encodeId=c8e72943e3d6, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Mar 09 06:00:25 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2018149, encodeId=4e352018149f3, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Fri Sep 28 17:35:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360390, encodeId=e5221360390f8, content=<a href='/topic/show?id=fe70965643d' target=_blank style='color:#2F92EE;'>#铁调素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96564, encryptionId=fe70965643d, topicName=铁调素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551129, encodeId=fd171551129d7, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608618, encodeId=4f0d1608618a9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294671, encodeId=f5702946e11f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 10 05:33:05 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294373, encodeId=c8e72943e3d6, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Mar 09 06:00:25 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
    2018-03-10 121832a9m88暂无昵称

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2018149, encodeId=4e352018149f3, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Fri Sep 28 17:35:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360390, encodeId=e5221360390f8, content=<a href='/topic/show?id=fe70965643d' target=_blank style='color:#2F92EE;'>#铁调素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96564, encryptionId=fe70965643d, topicName=铁调素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c94141, createdName=liuquanmn, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551129, encodeId=fd171551129d7, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608618, encodeId=4f0d1608618a9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 10 14:35:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294671, encodeId=f5702946e11f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 10 05:33:05 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294373, encodeId=c8e72943e3d6, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Fri Mar 09 06:00:25 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
    2018-03-09 changjiu

    学习了.谢谢

    0

相关资讯

外科医生手术的快与好

如果一个外科医生被称为“快刀”,是一种最高的礼赞,绝对触及到了外科医生最虚荣的神经,一搔就痒。

胡盛寿院士:推进中国心血管外科质量改善

随着时代的进步,患者对医疗服务的需求在不断变化,已由片面需求发展为全方位需要,已由有病可治和治好病发展为通过高质量的医疗服务回归身体与心理的双重健康。面对这一变化,我们不得不对当前医疗服务进行思考:为患者提供的技术是患者的最佳选择吗?为患者提供的服务是行业的最佳品质吗?为患者提供的诊疗有最佳的近远期效益吗?我们是否满足了患者对医疗服务的需求?

王海波教授:2017年乳腺癌外科领域热点问题的更新总结

保乳手术(breast conserving treatment, BCT)是目前早期浸润性乳腺癌的标准治疗手段之一,但是对手术切缘的界定始终存在争议。2014年外科肿瘤学会(Society of Surgical Oncology,SSO)和美国放射肿瘤学会(American Society for Radiation Oncology,ASTRO)颁布了《Ⅰ、Ⅱ期浸润性乳腺癌保乳手术的切缘指南

JAMA Surg:外科医生工作导致的肌肉骨骼疾病负担研究

研究认为临床外科医生工作相关的肌肉骨骼疾病负担十分严重

中国结直肠癌外科的3大问题,你是否也身陷其中?

回顾既往,手术技术的进步似乎并未带来肿瘤生存率的大幅提高,来自中国本土的外科领域高质量临床研究的数量也仍旧堪忧。

Lancet Infect Dis:多项干预措施联合应用有助于减少不发达地区手术部位感染

研究证实,多于基础医疗水平薄弱的不发达地区,多项手术部位感染预防干预措施可显著降低手术后感染风险